Dulaglutide FAQ: common questions answered
A weekly GLP-1 medicine approved for type 2 diabetes and lower heart-event risk.
Also called: Trulicity, LY2189265.
GLP-1 / GIP / glucagon agonists · GLP-1 receptor agonist · Evidence: Approved drug.
- Is Dulaglutide FDA-approved? Yes: Trulicity (type 2 diabetes age 10+; fewer major heart events in adults with diabetes and cardiovascular disease or multiple risk factors.). No US weight-management indication. March 2026 prescribing information checked.
- How do people take it? Under the skin, once weekly. Source: drug label.
- Can I take it with Metformin? Most AWARD studies used metformin background therapy for type 2 diabetes. Stomach symptoms can overlap; each drug retains its separate precautions. Source: studied in a trial. Ask a doctor before combining anything.
- Is it banned in sport? No, it is not on the banned list (WADA 2026). The 2026 monitoring program names semaglutide and tirzepatide, not this drug. Approved GLP-1 medicines remain permitted.
- How do I store it once opened? No mixing. May be kept below 30°C for a total of 14 days; discard after the single injection.
Related to Dulaglutide
- Semaglutide: A GLP-1 medicine with strong weight, glucose, heart and kidney evidence; dose and formulation matter.
- Tirzepatide: A weekly GIP/GLP-1 injection with strong diabetes and weight-loss evidence and common stomach side effects.
- Retatrutide: An experimental weekly injection with phase 3 weight-loss results.
- Liraglutide: A daily GLP-1 injection approved for weight management and type 2 diabetes.
- Exenatide: An older GLP-1 with twice-daily and weekly forms, now widely discontinued.
Sources
- 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2026, 2026
- Compounding and the FDA: Questions and Answers, FDA · FDA · 2026
- Consensus-based clinical and research recommendations for use of glucagon-like peptide-1 receptor agonists in the context of eating disorders: a modified Delphi study., Keshen A et al. · World psychiatry : official journal of the World Psychiatric Association (WPA) · 2026
- GLP-1 receptor agonists and dual GLP-1/GIP receptor agonists: strengthened warnings on acute pancreatitis, including necrotising and fatal cases, 2026
- The 2026 Monitoring Program, World Anti-Doping Agency · 2026
- Therapeutic Goods (Poisons Standard—October 2026) Instrument 2026, Australian Government · Australian Government · 2026
- TRULICITY, 2026
- Trulicity: pediatric type 2 diabetes, age 10+ — prescribing information, sections 1 and 2, DailyMed · 2026
- Weight Loss Drugs: What athletes need to know about GLP-1s, USADA · 2026
- Nutritional priorities to support GLP-1 therapy for obesity: A joint advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and the Obesity Society., Mozaffarian D et al. · Obesity pillars · 2025
- GLP-1 receptor agonists: reports of diabetic ketoacidosis when concomitant insulin was rapidly reduced or discontinued, 2019
- Product information
- Trulicity | European Medicines Agency (EMA)
- Comparison of Pediatric and Adult Glucagon-Like Peptide-1 Receptor Agonist Exposures Reported To United States Poison Centers, 2017-2024., Senthilkumar A et al. · Journal of medical toxicology : official journal of the American College of Medical Toxicology · 2026
- Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes., Nicholls SJ et al. · The New England journal of medicine · 2025
Sources checked: 2026-10-18.
Information only, not medical advice. Peptifacts does not sell anything and does not link to sellers.